Report : South & Central America Antibody Drug Conjugates Market Forecast to 2030 - Regional Analysis - By Technology (Cleavable Linker and Non-cleavable Linker), Application (Blood Cancer, Breast Cancer, Ovarian Cancer, Urothelial Cancer, and Others), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
At 14.8% CAGR, the South & Central America Antibody Drug Conjugates Market is Projected to be Worth US$ 799.23 Million by 2030, Says Business Market Insights
According to Business Market Insights research, the South & Central America antibody drug conjugates market was valued at US$ 264.91 million in 2022 and is expected to reach US$ 799.23 million by 2030, registering a CAGR of 14.8% from 2022 to 2030. Increasing investments to develop ADCs and increasing FDA approvals are among the critical factors attributed to the South & Central America antibody drug conjugates market expansion.
Developing products in the biopharmaceutical industry requires huge investments. ADCs are novel products that consume a long period for development, clinical trials, approvals, and commercialization. Developing a new molecule or product requires a minimum of 12 years with an investment of ~US$ 1-2 billion. There is an additional cost for regulatory procedures, as stringent regulations for new product development exist. Therefore, the cost of commercialized ADCs is considerably high; in most cases, they are not reimbursed. For instance, in November 2022, Immunogen announced that it would sell its drug conjugate, Elahere (mirvetuximab soravtansine), for US$ 6,220 per vial to treat ovarian cancer in adults. Immunogen also revealed that many patients will receive three to four vials of Elahere between US$ 18,500 and US$ 25,000/cycle. Elanhere is administered once in the 21-day treatment cycle. Similarly, Trodelvy, a breast cancer drug from Gilead, costs US$ 2,188 per vial. Trodelvy is given twice in the 21-day treatment cycle, and 10 mg/kg dosage is recommended based on the patients weight. Thus, the high cost of ADC development notably affects the cost of commercialization, and the dosage variation according to the patients weight hinders market growth.
On the contrary, high cost of ADCs development and commercialization hampers the growth South & Central America antibody drug conjugates market.
Based on technology, the South & Central America antibody drug conjugates market is bifurcated into cleavable linker and non-cleavable linker. The cleavable linker segment held 68.6% share of the South & Central America antibody drug conjugates market in 2022, amassing US$ 181.74 million. It is projected to garner US$ 541.21 million by 2030 to expand at 14.6% CAGR during 2022-2030.
Based on application, the South & Central America antibody drug conjugates market is segmented into blood cancer, breast cancer, ovarian cancer, urothelial cancer, and others. The breast cancer segment held 57.6% share of the South & Central America antibody drug conjugates market in 2022, amassing US$ 152.62 million. It is projected to garner US$ 473.93 million by 2030 to expand at 15.2% CAGR during 2022-2030.
Based on distribution channel, the South & Central America antibody drug conjugates market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held 70.3% share of South & Central America antibody drug conjugates market in 2022, amassing US$ 186.10 million. It is projected to garner US$ 575.45 million by 2030 to expand at 15.2% CAGR during 2022-2030.
Based on country, the South & Central America antibody drug conjugates market is categorized into Brazil, Argentina, the Rest of South & Central America. Brazil held 84.6% share of South & Central America antibody drug conjugates market in 2022, amassing US$ 223.98 million. It is projected to garner US$ 687.33 million by 2030 to expand at 15.0% CAGR during 2022-2030.
Key players operating in the South & Central America antibody drug conjugates market are Pfizer Inc, Hoffmann-La Roche Ltd, GSK Plc, Gilead Sciences Inc, AstraZeneca Plc, Astellas Pharma Inc, and Takeda Pharmaceutical Co Ltd, among others.
- In Mar 2023, Pfizer Inc. and Seagen Inc entered into a definitive merger agreement under which Pfizer will acquire Seagen, a global biotechnology company that discovers, develops, and commercializes transformative cancer medicines, for $229 in cash per Seagen share for a total enterprise value of $43 billion.
- In Sept 2023, Seagen Inc., a world leader and pioneer in antibody-drug conjugate (ADC) therapies, and RemeGen Co., Ltd. have entered into an exclusive worldwide licensing agreement to develop and commercialize disitamab vedotin, a novel HER2-targeted ADC. This collaboration leverages Seagens world-class expertise and knowledge of ADC development, manufacturing, and commercialization to maximize the potential of disitamab vedotin.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com